Following resistance to EGFR-TKI, subgroup analyses of an impower150 study indicated that EGFR-mutated NSCLC patients might benefit from the combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (15). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.